» Articles » PMID: 9653090

Interferon Gamma-independent Rejection of Interleukin 12-transduced Carcinoma Cells Requires CD4+ T Cells and Granulocyte/Macrophage Colony-stimulating Factor

Overview
Journal J Exp Med
Date 1998 Jul 7
PMID 9653090
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

We analyzed the ability of interferon (IFN)-gamma knockout mice (GKO) to reject a colon carcinoma transduced with interleukin (IL)-12 genes (C26/IL-12). Although the absence of IFN-gamma impaired the early response and reduced the time to tumor onset in GKO mice, the overall tumor take rate was similar to that of BALB/c mice. In GKO mice, C26/IL-12 tumors had a reduced number of infiltrating leukocytes, especially CD8 and natural killer cells. Analysis of the tumor site, draining nodes, and spleens of GKO mice revealed reduced expression of IFN- inducible protein 10 and monokine induced by gamma-IFN. Despite these defects, GKO mice that rejected C26/IL-12 tumor, and mice that were primed in vivo with irradiated C26/IL-12 cells, showed the same cytotoxic T lymphocyte activity but higher production of granulocyte/macrophage colony-stimulating factor (GM-CSF) as compared with control BALB/c mice. Treatment with monoclonal antibodies against GM-CSF abrogated tumor regression in GKO but not in BALB/c mice. CD4 T lymphocytes, which proved unnecessary or suppressive during rejection of C26/IL-12 cells in BALB/c mice, were required for tumor rejection in GKO mice. CD4 T cell depletion was coupled with a decline in GM-CSF expression by lymphocytes infiltrating the tumors or in the draining nodes, and with the reduction and disappearance of granulocytes and CD8 T cells, respectively, in tumor nodules. These results suggest that GM-CSF can substitute for IFN-gamma in maintaining the CD8-polymorphonuclear leukocyte cross-talk that is a hallmark of tumor rejection.

Citing Articles

Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.

Jou E Explor Target Antitumor Ther. 2023; 4(3):474-497.

PMID: 37455828 PMC: 10345208. DOI: 10.37349/etat.2023.00146.


A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.

Xue D, Moon B, Liao J, Guo J, Zou Z, Han Y Sci Immunol. 2022; 7(67):eabi6899.

PMID: 34995098 PMC: 9009736. DOI: 10.1126/sciimmunol.abi6899.


Tissue-resident cytotoxic innate lymphoid cells in tumor immunosurveillance.

Stamatiades E, Li M Semin Immunol. 2019; 41:101269.

PMID: 30904283 PMC: 6733035. DOI: 10.1016/j.smim.2019.03.001.


Lipid nanoparticles that deliver IL-12 messenger RNA suppress tumorigenesis in MYC oncogene-driven hepatocellular carcinoma.

Lai I, Swaminathan S, Baylot V, Mosley A, Dhanasekaran R, Gabay M J Immunother Cancer. 2018; 6(1):125.

PMID: 30458889 PMC: 6247677. DOI: 10.1186/s40425-018-0431-x.


Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells.

Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y F1000Res. 2016; 4.

PMID: 26918147 PMC: 4754024. DOI: 10.12688/f1000research.7010.1.


References
1.
Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A . Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol. 1992; 149(11):3627-35. View

2.
Cavallo F, Signorelli P, Giovarelli M, Musiani P, Modesti A, Brunda M . Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997; 89(14):1049-58. DOI: 10.1093/jnci/89.14.1049. View

3.
Dalton D, Keshav S, Figari I, Bradley A, Stewart T . Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science. 1993; 259(5102):1739-42. DOI: 10.1126/science.8456300. View

4.
Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C . Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med. 1993; 178(1):151-61. PMC: 2191097. DOI: 10.1084/jem.178.1.151. View

5.
Locksley R . Interleukin 12 in host defense against microbial pathogens. Proc Natl Acad Sci U S A. 1993; 90(13):5879-80. PMC: 46829. DOI: 10.1073/pnas.90.13.5879. View